Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Leukemia

• Publication date

  2003-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.leu.2403135PMID 14562125
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Retinoic Acid: Result of the Randomized MRC Trial All-Trans Predict Prognosis in Acute Promyelocytic Leukemia Treated With Presenting White Blood Cell Count and Kinetics of Molecular Remission

  2013cited by this paper
• Encyclopedia of Genetics

  2004cited by this paper
• Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia

  2003cited by this paper
• Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects

  2003cited by this paper
• Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia

  2003cited by this paper
• Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

  2003cited by this paper
• New drugs for therapy of AML

  2002cited by this paper
• The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

  2002cited by this paper
• Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay

  2002cited by this paper
• Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α

  2002cited by this paper
• Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.

  2002cited by this paper
• Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

  2002cited by this paper
• Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases

  2002cited by this paper
• Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts

  2002cited by this paper
• Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)‐positive acute myeloblastic leukemia by real‐time RT‐PCR

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Quantification of TEL–AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia

  2001cited by this paper
• Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach.

  2001cited by this paper
• Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction.

  2001cited by this paper
• Translocations of the RARalpha gene in acute promyelocytic leukemia.

  2001cited by this paper
• Pulsed ATRA as single therapy restores long-term remission in PML-RARα-positive acute promyelocytic leukemia patients: real time quantification of minimal residual disease. A pilot study

  2001cited by this paper
• Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction.

  2001cited by this paper
• Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.

  2001cited by this paper
• Polymerase Chain Reaction, Real-Time Quantitative

  2001cited by this paper
• Arsenic trioxide‐ and idarubicin‐induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot study

  2001cited by this paper
• Quantification of minimal residual disease in T-lineage acute lymphoblastic leukemia with the TAL-1 deletion using a standardized real-time PCR assay

  2001cited by this paper
• Translocations of the RARα gene in acute promyelocytic leukemia

  2001cited by this paper
• Kinetics of BCR‐ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real‐time polymerase chain reaction

  2001cited by this paper
• The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.

  2001cited by this paper
• Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial

  2001cited by this paper
• Perspectives on the future of chronic myeloid leukemia treatment.

  2001cited by this paper
• Quantification of CBFβ/MYH11 fusion transcript by Real Time RT-PCR in patients with INV(16) acute myeloid leukemia

  2001cited by this paper
• Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins

  2001cited by this paper
• Minimal residual disease in leukaemia patients.

  2001cited by this paper
• Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR

  2000cited by this paper
• A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood

  2000cited by this paper
• Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients.

  2000cited by this paper
• Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

  2000cited by this paper
• A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia.

  2000cited by this paper
• Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients.

  2000cited by this paper
• Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes

  2000cited by this paper
• Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission

  2000cited by this paper
• Real‐time quantitation of bcr‐abl transcripts in haematological malignancies

  2000cited by this paper
• AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.

  2000cited by this paper
• Detection and quantification of residual disease in chronic myelogenous leukemia

  2000cited by this paper
• Quantitation of minimal residual disease in t(8;21)‐positive acute myelogenous leukemia patients using real‐time quantitative RT‐PCR

  2000cited by this paper
• Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129.

  2000cited by this paper
• Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia

  2000cited by this paper
• Quantitative analysis of TEL/AML1 fusion transcripts by real-time RT-PCR assay in childhood acute lymphoblastic leukemia

  2000cited by this paper
• Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.

  2000cited by this paper
• PCR-detectable transcripts in long-term remission of P190(BCR/ABL)-positive acute lymphoblastic leukemia.

  2000cited by this paper
• Altered lymphoid development in mice deficient for the mAF4 proto-oncogene.

  2000cited by this paper
• Cytogenetically cryptic AML1–ETO and CBFβ–MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia

  2000cited by this paper
• Molecular genetics in acute leukemia

  2000cited by this paper
• Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia.

  2000cited by this paper
• Leukemogenesis by CBF oncoproteins

  1999cited by this paper
• Detection of recurrent translocations using real time PCR; assessment of the technique for diagnosis and detection of minimal residual disease.

  1999cited by this paper
• The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease

  1999cited by this paper
• Real‐time RT‐PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)‐positive AML patients

  1999cited by this paper
• No evidence for MLL/AF4 expression in normal cord blood samples.

  1999cited by this paper
• MLL-AF4 gene fusions in normal newborns.

  1999cited by this paper
• Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a ‘real time’ quantitative RT-PCR assay

  1999cited by this paper
• A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

  1999cited by this paper
• Monitoring treatment and survival in chronic myeloid leukemia. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation.

  1999cited by this paper
• Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real‐time RT‐PCR exemplified by t(12;21) TEL‐AML1 fusion transcript

  1999cited by this paper
• Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease

  1999cited by this paper
• TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification

  1999cited by this paper
• Acute myeloid leukemia.

  1999cited by this paper
• Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

  1999cited by this paper
• Therapy of molecular relapse in acute promyelocytic leukemia.

  1999cited by this paper
• The SCL gene: from case report to critical hematopoietic regulator.

  1999cited by this paper
• TEL/AML1 positivity in childhood ALL: average or better prognosis?

  1999cited by this paper
• The biology of chronic myeloid leukemia.

  1999cited by this paper
• Molecular monitoring of minimal residual disease in acute myeloblastic leukemia with t(8;21) by RT-PCR.

  1998cited by this paper
• Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties.

  1998cited by this paper
• Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay

  1998cited by this paper
• Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

  1998cited by this paper
• Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.

  1998cited by this paper
• Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.

  1998cited by this paper
• TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Münster Study Group.

  1998cited by this paper
• TEL-AML1 Fusion Transcript in Relapsed Childhood Acute Lymphoblastic Leukemia

  1998cited by this paper
• The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

  1998cited by this paper
• Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study.

  1998cited by this paper
• The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

  1998cited by this paper
• Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real‐time quantitative RT‐PCR

  1998cited by this paper
• Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation.

  1998cited by this paper
• Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia.

  1998cited by this paper
• Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

  1998cited by this paper
• E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study.

  1998cited by this paper
• TAL1 expression does not occur in the majority of T‐ALL blasts

  1998cited by this paper
• Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial

  1998cited by this paper
• Minimal residual disease in chronic myeloid leukaemia.

  1998cited by this paper
• Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis

  1998cited by this paper
• Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia

  1998cited by this paper
• Simultaneous SIL‐TAL1 RT‐PCR detection of all tald deletions and identification of novel tald variants

  1997cited by this paper
• Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse.

  1997cited by this paper
• Minimal residual disease with TEL‐AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21)

  1997cited by this paper
• Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation.

  1997cited by this paper
• Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials

  1997cited by this paper
• Defining the "absence" of the CBFbeta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions.

  1997cited by this paper

• Landscape of Measurable Residual Disease in Acute Myeloid Leukemia: From Molecular Detection to Clinical Practice

  2026cites this paper
• Utility of a Digital PCR-Based Gene Expression Panel for Detection of Leukemic Cells in Pediatric Acute Lymphoblastic Leukemia

  2026cites this paper
• Differential Prognosis and Transplant Strategies in CBF-AML With RUNX1::RUNX1T1 Versus CBFβ::MYH11 Fusions.

  2026cites this paper
• Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia

  2026cites this paper
• TGFβ-Mediated Overexpression of Podoplanin Serves as a Potential Diagnostic Biomarker in Acute Promyelocytic Leukemia.

  2026cites this paper
• A SYBR Green-Based Multiplex RT-qPCR Assay for the Simultaneous Screening of Prognostically Significant Translocations in Acute Lymphoblastic Leukemiafig

  2026cites this paper
• Emerging research themes in ferroptosis research for non-small cell lung cancer: a bibliometric and visualized analysis

  2025cites this paper
• 儿童急性T淋巴细胞白血病微小残留病研究现状及展望

  2025cites this paper
• KIT amplitude-based multiplex droplet digital polymerase chain reaction outperforms direct sequencing for sensitive KIT D816 genotyping in core binding factor acute myeloid leukemia.

  2025cites this paper
• Treatment-free remission in chronic myeloid leukemia with rare ABL1 gene fusions: Real-life study from the French CML group Fi-LMC.

  2025cites this paper
• New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers

  2025cites this paper
• Distribution of BCR::ABL1 transcript types and response to therapy in pediatric patients with chronic myeloid leukemia.

  2025cites this paper
• Evaluation of leukemic stem cell (CD26 +) in chronic myeloid leukemia patients with different molecular responses and in treatment-free remission

  2025cites this paper
• Minimal Residual Disease Detection: Implications for Clinical Diagnosis and Cancer Patient Treatment

  2025cites this paper
• Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.

  2025cites this paper
• Frequency and prognostic value of unconventional genetic subtypes in paediatric and young adult B‐cell precursor acute lymphoblastic leukaemia in Taiwan

  2025cites this paper
• Detection of leukemia gene fusions on DNA-level through targeted Next-Generation Sequencing

  2025cites this paper
• In Search for the Ideal All-Trans-Retinoic Acid Dose in Acute Promyelocytic Leukemia: Striking the Balance Between Drug Toxicity and Measurable Residual Disease Clearance

  2025cites this paper
• Clinical features and treatment response to TKIs in chronic myeloid leukemia patients with atypical BCR::ABL1 transcripts.

  2025cites this paper
• BCL‐6‐Positive Cutaneous Mantle Zone Hyperplasia: A Novel Subtype of B‐Cell Cutaneous Lymphoid Hyperplasia

  2025cites this paper
• Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype

  2025cites this paper
• Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis

  2025cites this paper
• Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.

  2025cites this paper
• Pattern of Expression of PML-RARα Transcripts in Acute Promyelocytic Leukemia Patients and Its Correlation with Overall Survival: A Retrospective Study from Western India

  2025cites this paper
• Identification of a novel PML exon 6 splice variant in atypical PML::RARα transcripts in acute promyelocytic leukemia

  2025cites this paper
• [Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].

  2025cites this paper
• ГЕНЕТИЧЕСКАЯ ДИАГНОСТИКА ГЕМОБЛАСТОЗОВ У ДЕТЕЙ В ГАУЗ «ЧЕЛЯБИНСКАЯ ОБЛАСТНАЯ ДЕТСКАЯ КЛИНИЧЕСКАЯ БОЛЬНИЦА» (2022-2024 гг.)

  2025cites this paper
• Pre- and post-transplant extramedullary involvement in adult patients with t(8;21)(q22;q22) acute myeloid leukemia: incidence, risk factors and outcomes

  2025cites this paper
• Benchmarking standard-of-care and emerging genomic approaches to enhance diagnosis in pediatric acute lymphoblastic leukemia

  2025cites this paper
• Coexistence of acute myeloid leukemia with a complex chromosomal translocation and monoclonal gammopathy of undetermined significance: A case report and literature review

  2025cites this paper
• 40 years of LEUKEMIA

  2025cites this paper
• Haploidentical Hematopoietic Stem Cell Transplantation for AML Patients with Persistent Molecular MRD

  2025cites this paper
• Detection of minimal residual disease in cryopreserved testicular tissue from (pre)pubertal boys with acute leukemia following first-line therapy.

  2025cites this paper
• Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges

  2025cites this paper
• Towards Routine Molecular Diagnostics: Multiplex SYBR Green Real-time PCR for Rapid Molecular Screening of Recurrent Translocations in Acute Myeloid Leukemia

  2025cites this paper
• A comparative analysis between real‐time polymerase chain reaction and next‐generation sequencing for the simultaneous detection of key fusions in acute myeloid leukaemia

  2025cites this paper
• Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as emerging technologies

  2025cites this paper
• Optimized Flow Cytometry Incorporating t-SNE Enables Minimal Residual Disease Assessment in a Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia at or Near the Lower Detection Limit.

  2025cites this paper
• Neo‐enhancers in T‐cell acute lymphoblastic Leukaemia (T‐ALL) and beyond

  2025cites this paper
• Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

  2024cites this paper
• Tailored digital PCR follow-up of rare fusion transcripts after initial detection through RNA-sequencing in hematological malignancies.

  2024cites this paper
• Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology

  2024cites this paper
• A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classifications.

  2024cites this paper
• Cysteine- and glycine-rich protein 1 predicts prognosis and therapy response in patients with acute myeloid leukemia

  2024cites this paper
• Morphoea presenting histopathologically as mycosis fungoides: an illustrative series of four cases

  2024cites this paper
• Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts

  2024cites this paper
• Refining risk stratification in paediatric B‐acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity

  2024cites this paper
• Molecular relapse monitoring reveals the domination of impaired NK cell education over impaired inhibition in missing KIR‐ligand recognition in patients after unrelated hematopoietic stem cell transplantation for malignant diseases

  2024cites this paper
• Measurable residual disease (MRD)-testing in haematological and solid cancers

  2024cites this paper
• Philadelphia chromosome‐positive B‐cell lymphoblastic lymphoma in a child: Case report and literature review

  2024cites this paper
• Clinical outcomes of early WT1 mRNA reduction after remission induction in newly diagnosed acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.

  2024cites this paper
• Evaluating testicular tissue for future autotransplantation: focus on cancer cell contamination and presence of spermatogonia in tissue cryobanked for boys diagnosed with a hematological malignancy.

  2024cites this paper
• Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.

  2024cites this paper
• Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach

  2024cites this paper
• Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia

  2024cites this paper
• Early T-cell precursor acute lymphoblastic leukemia: diagnostic pitfalls, genomic alteration, novel therapeutics, and minimal residual disease monitoring

  2024cites this paper
• Risk stratification in the clinical application of minimal residual disease assessment in acute myeloid leukemia

  2024cites this paper
• Molecular techniques in haematopathology: what and how?

  2024cites this paper
• Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development

  2024cites this paper
• Acute promyelocytic leukemia as a differential diagnosis of Crimean-Congo hemorrhagic fever

  2024cites this paper
• New practice of BCR::ABL1 standardization system based on p210 and p190 BCR::ABL1 reference materials.

  2024cites this paper
• IGH::NSD2 Fusion Gene Transcript as Measurable Residual Disease Marker in Multiple Myeloma

  2024cites this paper
• Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression

  2024cites this paper
• Non-Mutational Changes of Autophagy Marker LC3A in Patients with Acute Myeloid Leukemia; Effect of DNA Methylation and Expression Level of LncRNA-GAS5 and miRNA-155-5p, A Case Control Study

  2024cites this paper
• SJPedPanel: A Pan-Cancer Gene Panel for Childhood Malignancies to Enhance Cancer Monitoring and Early Detection

  2024cites this paper
• Variant‐specific BCR::ABL1 quantification discrepancy in chronic myeloid leukemia

  2024cites this paper
• Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?

  2024cites this paper
• Three-Way Translocation t(12;15;17) (p13;q24;q21) Found in Acute Promyelocytic Leukemia with Basophilic Differentiation

  2024cites this paper
• Combination Treatment of Resistant Acute Promyelocytic Leukemia Cells with Arsenic Trioxide and Anti-Apoptotic Gene Inhibitors

  2024cites this paper
• The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia

  2024cites this paper
• A complete oral regimen for induction therapy of patients with high‐risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy

  2024cites this paper
• Measuring response to therapy in AML: Difference from normal flow cytometry vs RQ-PCR.

  2024cites this paper
• Technical challenges for standardization of molecular monitoring in chronic myeloid leukaemia in developing countries

  2024cites this paper
• RAPID-CRISPR: highly sensitive diagnostic assay for detection of PML::RARA isoforms in acute promyelocytic leukemia

  2024cites this paper
• Molecular Methods: Clinical Utilization and Designing a Test Menu.

  2024cites this paper
• Evaluation of next-generation sequencing for measurable residual disease monitoring in three major fusion transcript subtypes of B-precursor acute lymphoblastic leukaemia.

  2024cites this paper
• Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.

  2024cites this paper
• Minimal residual disease monitoring in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia: prognostic significance and correlation between multiparameter flow cytometry and real-time quantitative polymerase chain reaction

  2024cites this paper
• Fully Automated GeneXpert BCR-ABL1 Assay versus Standard Nonautomated BCR-ABL1 Real-Time Reverse Transcription–Polymerase Chain Reaction Quantitation: A Study from Tertiary Care Institute in India

  2024cites this paper
• Acute promyelocytic leukemia with PML/RARA (bcr1, bcr2 and bcr3) transcripts in a pediatric patient

  2024cites this paper
• Evaluation of oxidative stress and genetic instability among residents near mobile phone base stations in Germany.

  2024cites this paper
• Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study

  2024cites this paper
• A temporal cluster of acute promyelocytic leukemia

  2023cites this paper
• Laboratory Aspects of Minimal / Measurable Residual Disease Testing in B-Lymphoblastic Leukemia.

  2023cites this paper
• Measurable residual disease after CAR T-cell therapy.

  2023cites this paper
• Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML

  2023cites this paper
• Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study

  2023cites this paper
• Design and Validation of a Custom Next-Generation Sequencing Panel in Pediatric Acute Lymphoblastic Leukemia

  2023cites this paper
• Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study

  2023cites this paper
• Antigen Receptors Gene Analysis for Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia: The Role of High Throughput Sequencing

  2023cites this paper
• Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia

  2023cites this paper
• Molecular Heterogeneity of Pediatric AML with Atypical Promyelocytes Accumulation in Children—A Single Center Experience

  2023cites this paper
• Guidelines for the use of flow cell sorting in diagnosis and monitoring of acute leukemia

  2023cites this paper
• Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro

  2023cites this paper
• Specific High-Sensitivity Enzymatic Reporter UnLOCKing-Mediated Detection of Oncogenic BCR::ABL1 and EGFR Rearrangements

  2023cites this paper
• Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis.

  2023cites this paper
• Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest

  2023cites this paper
• SJPedPanel: A pan-cancer gene panel for childhood malignancies

  2023cites this paper
• Different Isoforms of PML-RARA Chimeric Protein in Patients with Acute Promyelocytic Leukemia: Survival Analysis per Demographic Characteristics, Clinicohematological Parameters, and Cytogenetic Findings

  2023cites this paper
• Effects of low-dose ionizing radiation on genomic instability in interventional radiology workers

  2023influential citation